Recent News

• 06.12.2025 - Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
• 06.12.2025 - June 12, 2025 - June 15, 2025 : EHA 2025: Investor Event
• 06.09.2025 - 46th Annual Goldman Sachs Global Healthcare Conference
• 06.09.2025 - 46th Annual Goldman Sachs Global Healthcare Conference
• 06.06.2025 - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2025 - Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

Recent Filings

• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2025 - 8-K Current report
• 06.05.2025 - 4 Statement of changes in beneficial ownership of securities